Home  »  Hot Stocks   »  The Volatility of Novo Nordisk A/S’s (NVO) S...

The Volatility of Novo Nordisk A/S’s (NVO) Stock: A -4.04% Ratio for the Week

The stock of Novo Nordisk A/S (NVO) has gone down by -4.04% for the week, with a -1.97% drop in the past month and a 14.22% rise in the past quarter. The volatility ratio for the week is 1.93%, and the volatility levels for the past 30 days are 1.54% for NVO. The simple moving average for the past 20 days is -3.29% for NVO’s stock, with a 23.08% simple moving average for the past 200 days.

Is It Worth Investing in Novo Nordisk A/S (NYSE: NVO) Right Now?

The price-to-earnings ratio for Novo Nordisk A/S (NYSE: NVO) is 41.61x, which is above its average ratio. Moreover, the 36-month beta value for NVO is 0.48. Analysts have varying opinions on the stock, with 15 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 3 as “sell.”

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


The average price recommended by analysts for Novo Nordisk A/S (NVO) is $171.80, which is $8.17 above the current market price. The public float for NVO is 1.18B and currently, short sellers hold a 0.13% of that float. On May 25, 2023, NVO’s average trading volume was 1.43M shares.

NVO) stock’s latest price update

The stock of Novo Nordisk A/S (NYSE: NVO) has decreased by -0.02 when compared to last closing price of 161.78. Despite this, the company has experienced a -4.04% fall in its stock price over the last five trading sessions. The Wall Street Journal reported on 03/14/23 that Novo Nordisk to Slash Insulin Prices by Up to 75%

NVO Trading at -0.02% from the 50-Day Moving Average

After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.49% of loss for the given period.

Volatility was left at 1.54%, however, over the last 30 days, the volatility rate increased by 1.93%, as shares sank -2.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.59% upper at present.

During the last 5 trading sessions, NVO fell by -4.15%, which changed the moving average for the period of 200-days by +54.45% in comparison to the 20-day moving average, which settled at $167.02. In addition, Novo Nordisk A/S saw 19.51% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for NVO

Current profitability levels for the company are sitting at:

  • +42.06 for the present operating margin
  • +82.50 for the gross margin

The net margin for Novo Nordisk A/S stands at +31.38. The total capital return value is set at 72.02, while invested capital returns managed to touch 57.99. Equity return is now at value 77.70, with 25.70 for asset returns.

Based on Novo Nordisk A/S (NVO), the company’s capital structure generated 30.88 points at debt to equity in total, while total debt to capital is 23.60. Total debt to assets is 10.69, with long-term debt to equity ratio resting at 29.13. Finally, the long-term debt to capital ratio is 22.25.

When we switch over and look at the enterprise to sales, we see a ratio of 13.62, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 3.79 and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.


To wrap up, the performance of Novo Nordisk A/S (NVO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.